Actively Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Led by Repertoire Immune Medicines · Updated on 2026-02-17
150
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
CONDITIONS
Official Title
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not treatable with curative intent.
- At least one measurable lesion according to RECIST v1.1 as assessed by the investigator.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function as defined in the trial protocol.
- Ability to provide written informed consent and comply with trial procedures.
You will not qualify if you...
- History of another malignancy within 3 years prior to the first dose of trial treatment, except certain cured skin cancers or in situ malignancies.
- Known active leptomeningeal disease or uncontrolled central nervous system metastases.
- Active, clinically significant autoimmune diseases requiring systemic immunosuppressive therapy.
- Prior allogenic organ transplantation.
- Clinically significant uncontrolled medical or psychiatric conditions that may increase risk or interfere with trial participation.
- Other protocol-defined inclusion and exclusion criteria apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here